Objective: The best course of treatment for recurrent ovarian cancer is uncertain. We sought to determine whether secondary cytoreductive surgery for first recurrence of ovarian cancer improves overall survival compared with other treatments.
BACKGROUND
The majority of ovarian cancers are diagnosed at late stage and initially respond to platinum-based chemotherapy; unfortunately most recur. 1, 2 For women experiencing recurrent ovarian cancer, the best course of treatment is uncertain. Typically, recurrent cancer is treated with chemotherapy but starting in the early 1990s, secondary cytoreductive surgery (SCS) appeared as a treatment option. 3 By 1996, the National Comprehensive Cancer Network guidelines incorporated SCS as a treatment choice along with chemotherapy despite lack of randomized trial data of its efficacy. 4 A recent Cochrane review of secondary surgery for recurrent epithelial ovarian cancer concludes that existing findings are inconclusive. 5 Most of the studies were single institutional case reports and few reported survival comparing surgery with chemotherapy. No study was population based. As 46% of ovarian cancer cases occurred in women 65 years and older, 1 SEER-Medicare data offers an opportunity to assess survival benefits of secondary surgery over chemotherapy alone. However, such explorations have been hampered by the limitations of administrative data-lack of specific procedure codes for recurrences or SCS, the challenge of identifying recurrent cancer, a condition without a specific diagnostic code. Although evidence of a second round of surgery may be used to identify recurrences, this approach has the potential to misclassify untreated patients as nonrecurrence. In addition, there is the inherent observational bias of healthier individuals receiving more aggressive treatments. Randomized trials comparing chemotherapy with secondary surgery are underway but results are years away. To help inform decision-making for women with recurrent ovarian cancer, we performed a population-based analysis of secondary surgical treatment compared with chemotherapy and with hospice using doubly robust regression methods, a novel multiple treatment propensity score methods to account for selection into treatment, and finite mixture survival models to account for potential misclassification of nonrecurrence.
MATERIALS AND METHODS

Cohort Selection
We used linked SEER-Medicare data for ovarian cancer cases diagnosed from January 1, 1997 to December 31, 2007 with claims and mortality data through 2010 (N = 35,995). We excluded women with more than 1 primary cancer (N = 5806), nonepithelial ovarian cancer cases (N = 871), those diagnosed before 1997 (N = 956) as well as women who received the diagnosis at autopsy or on death certificate (N = 16). We excluded women not enrolled in both Medicare parts A (inpatient) and B (outpatient) and those enrolled in a health maintenance organization (N = 4150) as they do not have complete Medicare fee-for-service claims. We also excluded women with early stage cancer (N = 10,952) who have a low likelihood of recurrence. Because we aimed to assess the effect of secondary debulking surgery for recurrent cancer, we included only who had undergone primary debulking for their primary ovarian cancer treatment. As we aimed to assess the comparative effectiveness of secondary surgery versus chemotherapy for recurrence, we included those treated optimally for their primary ovarian cancer, meaning those who underwent primary surgery and chemotherapy. Finally, we limited the analyses to women Z66 years (N = 5310) to capture comorbidities during the year before cancer diagnosis.
Identifying Secondary Surgery and First Recurrence
We obtained codes used by gynecologic oncology billers from centers in the Northeast, mid-Atlantic, Southeast, Midwest, Southwest, Pacific, and Pacific Northwest (list in Appendix 1, Supplemental Digital Content 1, http://links. lww.com/AJCO/A135) for SCS. A chart validation of these codes revealed a sensitivity of 77% and specificity of 92%. 6 To identify recurrent cancer, we created an algorithm based on expert gynecologic oncology opinion and the literature 5, 7, 8 that incorporates timing and utilization of either secondary surgery or chemotherapy. Recurrent cancer was defined by the presence of claims for secondary surgery, chemotherapy, or hospice after a 180-day treatment-free window after completion of primary course of therapy to distinguish between recurrent and persistent disease. We used diagnosis (ICD9) and procedure (CPT/Medicare HCPCS) codes for chemotherapy regimens commonly administered for recurrent ovarian cancer culled from gynecologic oncology billers (Appendix 2, Supplemental Digital Content 2, http://links.lww.com/AJCO/A136). Chart validation of a diagnosis recurrent ovarian cancer using this algorithm yielded a sensitivity of 100% and specificity of 89%. 6 
Treatment
We identified primary treatment searching Medicare claims from 30 days before 120 days after the date of diagnosis. As SEER reports only month and year of the diagnoses, the diagnosis date was assigned the 15th day of the month. We identified primary surgical treatment in inpatient files using ICD-9 procedure and outpatient and physician files using HCPCS codes, and receipt of chemotherapy using inpatient, outpatient, physician claims, and Durable Medical Equipment files. Primary chemotherapy was the first chemotherapy that occurred within 180 days before and 90 days after surgical treatment. Chemotherapy claims from all sources within 3 days were grouped into 1. To distinguish between persistent and recurrent cancer, there had to be a 6-month treatment-free window after completion of primary treatment.
Treatment Groups
We classified treatment for recurrent cancer into 4 categories: secondary surgery (with or without chemotherapy), chemotherapy only, hospice, no treatment. A small number of women (N = 26) appear to have had secondary surgery without chemotherapy. In preliminary analysis we dropped these observations from the analysis sample. As there were no substantive differences between this and our final sample in terms of means of explanatory variables or treatment effects, we included them with secondary surgery and chemotherapy group.
Sociodemographic and Clinical Variables
Age, race, SEER geographic region, year of diagnosis, tumor grade, histology, and stage are from SEER. We used median household income of the woman's residence zipcode. We assessed comorbidity using Elixhauser 9 and Charlson 10 indices to take into account both risk of in-hospital and longer term mortality and used comorbidities identified in inpatient and outpatient claims in the year before diagnosis of cancer.
Outcome
Overall survival was measured from the 15th day of the month of diagnosis to the date of death from any cause as reported in the Medicare database. Observations were censored at December 31, 2010, the last recorded date of follow-up in Medicare records.
Statistical Analysis
We use propensity score methods for multiple treatments 11 to minimize bias from selection into treatment. We estimate a multinomial logit model of treatments controlling for relevant socioeconomic and clinical characteristics such as age, race, income, stage, histology, comorbidity, diagnosis year, and SEER region to predict type of treatment (surgery, chemotherapy, hospice, none) received. We use the estimated parameters to create inverse propensity score weights.
We use finite mixture log-logistic survival models to assess the association of type of therapy with survival while controlling for propensity scores using inverse probability weighting.
The survival models also control for socioeconomic and clinical characteristics, thus the treatment effects obtained are doubly robust. 12 Finite mixture models allow for estimation of survival differences between treatment groups while differentiating the truly nonrecurrent cases from those women who did experience a recurrence but were misclassified because they did not receive SCS, chemotherapy, or hospice care.
Finite mixture models have been used to model cancer survival, 13, 14 and have many applications in other areas of health services, biology, marketing, and engineering. [15] [16] [17] [18] This approach distinguishes between individuals with a greater probability to be in one group as compared with another, such as those with longer versus shorter survival. Parametric survival analyses were used to identify distributions that provided the best fit to the data. Commonly used distributions including exponential, Weibull, log-normal, and log-logistic curves were tested, and the fit of each was assessed by using the Akaike information criterion criterion. These analyses showed that a log-logistic survival model fit the data best. The estimated parametric survival curves were also very close to observed Kaplan-Meier curves. Therefore, we used log-logistic distributions to construct the finite mixture model of survival allowing for 2 classes (types) of observations. Both the class probability and determinants of survival for each class (including effect of treatment) were estimated simultaneously using inverse propensity score weighted maximum likelihood.
RESULTS
Of the 7934 women, 3439 underwent primary cytoreductive surgery and chemotherapy, standard optimal treatment for a new ovarian cancer. Of these, 1401 had persistent cancer, defined as receiving treatment for ovarian cancer within 6 months of completing their primary treatment, and were excluded. The final sample included 2038 women (see CONSORT Fig. 1 ).
Treatments Table 1 shows the characteristics of women by treatment status in the sample and also weighted by the inverse propensity score obtained from multinomial logit regressions. Propensity weighted analyses resulted in similarly matched groups. Of the 1635 women who experience recurrence, 16% were treated with SCS and chemotherapy, 72% with chemotherapy alone, and 12% received hospice care. Younger women and those with fewer comorbidities were more likely to undergo surgery. There was no racial difference in treatment receipt. There was geographic variation with higher rates of SCS in the West. On average, women enrolled in hospice were older, had more comorbidities and were more likely to have metastatic disease. Women in the no treatment/no recurrence group tended to be younger, less likely to have stage 4 and have a slightly higher income. Year of diagnosis was not associated with treatment type and rates of SCS did not increase during the 1997 to 2007 time period (P = 0.33) ( Table 2) . Although there are numerous statistically significant differences in baseline characteristics across treatments in the sample, these differences become much smaller and always statistically insignificant once the sample is weighted using inverse propensity score weights (Table 1) . Although there was a statistically significant difference in median time from diagnosis to recurrence between women treated for recurrence with chemotherapy versus surgery (643 vs. 694 d; P = 0.007), there remains a significant difference in time between recurrence and death for those treated with chemotherapy versus surgery (660 vs. 1097 d; P < 0.0001).
Survival Analyses
Actual survival is shown in Figure 2 . Survival for women who underwent secondary debulking with chemotherapy was better compared with those who received chemotherapy only. In both unadjusted for propensity of treatment and propensity weighted analyses, treatment type, and younger age were associated with improved survival (Table 3) . Propensity score adjusted log-logistic analyses showed that women undergoing surgery with chemotherapy had significantly greater survival compared with those receiving chemotherapy alone (hazard ratio [HR] = 1.33; 95% confidence interval [CI], 1.20-1.47. Women receiving no secondary treatment, classified as nonrecurrent, had significantly better survival (HR = 2.33; 95% CI, 1.97-2.76), whereas women in hospice had significantly lower survival than those who underwent chemotherapy alone (HR = 0.55; 95% CI, 0.51-0.59). The estimated median survival of women treated with chemotherapy was 4.1 years from time of diagnosis; 77% of this group died within the study period. Those treated with secondary surgery and chemotherapy survived a median of 5.4 years; 67% died. Those receiving hospice survived an average of 2.2 years; 99% died. The 403 women who received no secondary treatments were classified as nonrecurrent and had a median survival of 9.3 years; 19.6% died (Fig. 3) . However, the group that received no secondary treatments and was classified as nonrecurrent, likely included women who were truly nonrecurrent and those with recurrence who went untreated and were misclassified. Estimation of a 2-class finite mixture log-logistic survival model, including the factors listed in Table 1 , identified 2 distinct classes of women with different survival (Table 3 ) with associated class probabilities of 75% (95% CI, 62%-85%) and 25% (95% CI, 18%-35%), respectively. The survival ratios, relative to chemotherapy, for observations in the 2 classes are 3.91 (95% CI, 2.88-5.31) for the truly nonrecurrent and 0.57 (95% CI, 0.42-0.78) for those misclassified as nonrecurrent who went untreated. Survival ratios for chemotherapy and surgery and for hospice are not significantly different across the 2 classes and are qualitatively very similar to those obtained from the standard log-logistic survival model described above. However, survival ratios for the no-treatment group is significantly different between the log-logistic and finite mixture models (HR = 2.3 vs. 3.9 vs. 0.57; P < 0.000). Median survival was 15.9 years for the truly nonrecurrent with longer survival as compared with 2.4 years in the group misclassified as nonrecurrent, those with shorter survival (Fig. 3) . Of the untreated women who were likely misclassified as nonrecurrent cancer, 55% listed cancer as their cause of death.
Most of the control covariates were not statistically significant determinants of survival. However, women with more comorbidities, higher grade cancer, or older had worse survival (Table 3) .
DISCUSSION
Ovarian cancer patients are living longer than they did 30 years ago with 5-year survival rates increasing from 20% to 40%. 19, 20 Although some of the improved survival is likely due to platinum-based therapies, the role of secondary surgery in improving survival has been uncertain. Many case studies and a recent Cochrane review suggest its effectiveness 5 but there has not been a population-based study that takes into account the potential observational biases inherent in cohort studies. 20 Our population-based findings suggest that treating first recurrence of ovarian cancer with secondary surgery and chemotherapy increases survival by >1 year compared with chemotherapy alone. Although randomized-controlled trial data are the gold standard for assessing treatment efficacy, eligibility limitations often make it difficult to apply findings to broader populations, particularly the elderly. Comparing effectiveness of treatments using population-based data can help inform physician and patient decision-making pending results of ongoing randomized phase 3 trials. 21 Our findings pertain to women 66 years and older who represent a substantial portion of ovarian cancer in the United States. Yet, we expect these findings may be useful for younger women who tend to have less comorbidity and may be better surgical candidates.
Our finding of less aggressive treatments among older and sicker patients is consistent with the literature of primary treatment of ovarian cancer. [22] [23] [24] [25] [26] Although others have described a racial disparity in primary treatment of ovarian cancer, 22, 27 we did not see this pattern for secondary treatments, perhaps because we limited this analysis to those patients who received optimal primary therapy.
A key challenge to evaluating the effectiveness of secondary treatments lies in the difficulty of accurately identifying secondary surgery and recurrent cancer. We approached and overcame these challenges with 2 methods-the first, a chart validation study that yielded excellent sensitivity and specificity of the coding algorithm. Although the algorithm was based on data billing codes from across the country and appears accurate, it was validated using a single institution's charts and may not work as well in other settings. Secondary surgery codes are further confounded by second look procedures which, despite improvements in imaging techniques, continue to be done to ensure that no lesions remain. This surgery can include removal of tissue for pathologic review which can be for diagnostic and treatment purposes. Because the vast majority of secondary surgeries in our cohort were accompanied by chemotherapy, it is unlikely that there was much misclassification. Similarly, we may have misclassified women with persistent cancer as they may have been receiving ongoing maintenance therapy. We believe such misclassification is unlikely since this group had a shortened median survival time (1.6 y), which is consistent with persistent disease. In addition, to further maximize our ability to assess effectiveness of secondary surgery for recurrent disease, we excluded women with persistent disease-those who continued to receive chemotherapy beyond the usual 6 months postprimary surgery. That our sample included only 265 women undergoing secondary surgery yet finds significant survival differences suggests the potential strength of the association found. Rates of performance may differ in a younger population. As with all administrative claims based analyses, our findings are limited by the inherent unmeasured biases of observational data. We used standard inverse propensity weighted analytic methods to reduce the impact of such biases, but may not eliminate them.
We recognize the inherent difficulty of classifying recurrent cancer by the presence of claims for treatment. Particularly in an elderly population, many women will go untreated when cancer recurs resulting in distorted survival estimates. To counter this challenge, we used finite mixture models, a novel approach to separate out the truly nonrecurrent from those with recurrence who forego active or hospice treatment. By utilizing this approach with persistent cancer, we obtain more accurate measures of survival among women who truly did not experience a recurrence, a count that is not obscured by the inclusion of those with recurrence who went untreated.
In summary, for women with advanced ovarian cancer initially treated with surgery and chemotherapy who experience a recurrence, SCS with chemotherapy appears to provide a significant survival advantage over chemotherapy alone and may be considered a standard of care pending results of ongoing randomized trials.
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